Ladenburg Thalmann Financial Services’s Theriva Biologics TOVX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$0	Sell	1 -11	-92%	-$1.17K	﹤0.01%	5497
2019 Q3	$1K	Hold	12	–	–	﹤0.01%	5165
2019 Q2	$2K	Hold	12	–	–	﹤0.01%	5005
2019 Q1	$2K	Hold	12	–	–	﹤0.01%	4968
2018 Q4	$2K	Sell	12 -9	-43%	-$2.14K	﹤0.01%	4932
2018 Q3	$13K	Hold	21	–	–	﹤0.01%	4154
2018 Q2	$58K	Hold	21	–	–	﹤0.01%	3165
2018 Q1	$58K	Hold	21	–	–	﹤0.01%	3165
2017 Q4	$92K	Hold	21	–	–	﹤0.01%	2788
2017 Q3	$169K	Buy	21 +6	+40%	+$34.7K	﹤0.01%	2231
2017 Q2	$74K	Hold	15	–	–	﹤0.01%	2718
2017 Q1	$83K	Buy	15 +5	+50%	+$34.9K	﹤0.01%	2527
2016 Q4	$67K	Hold	10	–	–	﹤0.01%	2632
2016 Q3	$148K	Hold	10	–	–	﹤0.01%	1965
2016 Q2	$153K	Hold	10	–	–	﹤0.01%	1847
2016 Q1	$201K	Buy	10 +4	+67%	+$60.1K	﹤0.01%	1606
2015 Q4	$115K	Hold	6	–	–	﹤0.01%	1954
2015 Q3	$114K	Buy	+6	New	+$148K	﹤0.01%	1888

Other funds holding TOVX

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

SCA

Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Ladenburg Thalmann Financial Services's TOVX Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services reduced its Theriva Biologics (TOVX) stake by 92% in Q4 2019, selling an estimated $1.17K and leaving 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5497.

Ladenburg Thalmann Financial Services first reported a position in TOVX in Q3 2015 and has held it in 18 quarters since. The position peaked at $201K in Q1 2016. 17 funds tracked by Wall St. Rank hold TOVX as of Q4 2019.

Ladenburg Thalmann Financial Services held 1 share of Theriva Biologics worth $0 as of Q4 2019.
Ladenburg Thalmann Financial Services sold 11 Theriva Biologics shares in Q4 2019, an estimated $1.17K.
Theriva Biologics made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #5497 holding.
Ladenburg Thalmann Financial Services first reported a position in Theriva Biologics in Q3 2015 and has held it in 18 quarters since.
Ladenburg Thalmann Financial Services's Theriva Biologics position peaked at $201K in Q1 2016.
17 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.